Farnesyltransferase inihibitors in hematologic malignancies
- PMID: 17293017
- DOI: 10.1016/j.blre.2006.12.001
Farnesyltransferase inihibitors in hematologic malignancies
Abstract
Farnesyltransferase inhibitors (FTIs) inhibit certain cellular signal transduction pathways, and are being evaluated for activity in hematologic malignancies. Tipifarnib and lonafarnib are orally available FTIs that are active against a variety of targets and inhibit several pathways involved in the pathogenesis of hematologic malignancies. FTIs have demonstrated activity in a variety of hematologic diseases, including acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and multiple myeloma. This article reviews the clinical experience with tipifarnib and lonafarnib in the treatment of hematologic malignancies.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
